2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

Abstract Number: 1585

Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Disease-Modifying Anti-Rheumatic Drug Therapy: A Retrospective Cohort Study Using UK Primary Care Electronic Medical Records
Abstract Number: 2635

Validating Arthroscopic Findings Using Histology, Status for Erosive Disease, and CRP in RA
Abstract Number: 755

Validating the RAIL Algorithm in Adult Lupus Nephritis Patients
Abstract Number: 2734

Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients
Abstract Number: 100

Validation of a Distinct Psoriatic Arthritis Risk Variant at IL23R
Abstract Number: 115

Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening
Abstract Number: 165

Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis
Abstract Number: 1444

Validation of a Revised Version of the Michigan Body Map
Abstract Number: 379

Validation of a Short Calcium Intake List to Estimate Daily Dietary Calcium Intake of Patients with Osteoporosis
Abstract Number: 2393

Validation of a Web-Based Overlay for Sectoral Scoring of Active Lesions on MRI in Hip Osteoarthritis: Femoral Bone Marrow Lesions Predict Response to Intra-Articular Hyaluronate
Abstract Number: 95

Validation of Differential Methylation in Paternally Versus Maternally Transmitted Psoriatic Disease
Abstract Number: 787

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus
Abstract Number: 1916

Validation of Novel Biomarker Candidates for Systemic Sclerosis
Abstract Number: 3151

Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Modules for Use in Childhood-Onset Lupus
Abstract Number: 2662

Validation of the Quickdash in the Assessment of Rheumatoid Arthritis Disease Activity
Abstract Number: 284

Validation of the Sporadic Inclusion Body Myositis Physical Functioning Assessment
Abstract Number: 166

Validity and Sensitivity to Change of the Semi-Quantitative Omeract Ultrasound Scoring System for Tenosynovitis in Patients with Rheumatoid Arthritis
Abstract Number: 1191

Validity Evidence for Two Objective Structured Clinical Examination Stations to Assess Core Examination Skills of the Shoulder and Knee
Abstract Number: 672

Validity of Ankylosing Spondylitis Diagnoses in the Health Improvement Network
Abstract Number: 52

Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian As Patients
Abstract Number: 120

Validity of the Inpatient Diagnosis of Systemic Lupus Erythematosus: Clarifying Hospital Readmission Rates
Abstract Number: 1340

Value of 18F-FDG PET for Therapeutic Assessment in Patients with Polymyalgia Rheumatica Treated in First Line By Tocilizumab
Abstract Number: 564

Value of Antinuclear Antibodies As a Predictor of Therapeutic Efficacy of Biologics in Rheumatoid Arthritis
Abstract Number: 1597

Variability in Health Assessment Questionnaire Based on Type of Health Insurance Coverage and Rheumatology Practice
Abstract Number: 680

Variability over Time in Patient-Reported Outcome Measures in Patients with Ankylosing Spondylitis
Abstract Number: 92

Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis
Abstract Number: 59

Variation in Heart Failure Hospitalizations Among U.S. Medicaid Recipients with SLE 2000-2010, By Race and Ethnicity
Abstract Number: 2388

Variations in Hip Morphology Are Associated with Hip Symptoms: Preliminary Results from a Large Community-Based Cohort
Abstract Number: 2694

Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Abstract Number: 2429

Varicella Vaccination in Patients with Pediatric Rheumatic Diseases Receiving Immunosuppression: Proposal of a Pre-Vaccination Checklist to Ensure Safety
Abstract Number: 2799

Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE
Abstract Number: 3046

Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease
Abstract Number: 1259

Verification of Haptoglobin and Von Willebrand Factor As Potential Biomarkers of Knee Osteoarthritis Using a Targeted Proteomics Approach in Serum
Abstract Number: 2065

Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Abstract Number: 364

Very High Frequency of Fragility Fractures Associated with High-Dose Glucocorticoids in Postmenopausal Women: A Retrospective Study
Abstract Number: 2392

Vibration Perception Threshold and Hip Osteoarthritis in Multicenter Ostoearthritis Study
Abstract Number: 1679

Vicm Is a Novel Biomarker of Macrophage Activity Evaluated in a Phase IIb Clinical Trial of Mavrilimumab
Abstract Number: 2436

Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community
Abstract Number: 3150

Virtual Peer-to-Peer Mentoring Support for Adolescents with Juvenile Idiopathic Arthritis: The Virtual Peer-to-Peer Program
Abstract Number: 1823

Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation
Abstract Number: 2648

Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy
Abstract Number: 3174

Vitamin D Binding Protein and Tenofovir-Associated Bone Loss Among Individuals with HIV
Abstract Number: 675

Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Abstract Number: 2231

Vitamin D Deficiency States Can be Actively Prevented. Results from a Cross-Sectional Study of over 3000 Patients with Rheumatic Diseases
Abstract Number: 2678

Vitamin D Serum Level in Early Arthritis Patients: Association with Disease Activity, Disability and Severity in the Espoir Cohort
Abstract Number: 2958

Vitamin D, Cognition and Cerebral Structural Abnormalities in Childhood- Onset Systemic Lupus Erythematosus
Abstract Number: 240

Volumetric Assessment of Tophaceous Gout

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].